GAMA
BCRX icon

Graticule Asia Macro Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-66,000
Closed -$1.04M – 107
2021
Q2 		$1.04M Sell
66,000
-34,000
-34% -$462K 0.31% 78
2021
Q1 		$1.02M Buy
+100,000
New +$1.03M 0.17% 115

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graticule Asia Macro Advisors's BCRX Position: Q3 2021 in Review

Graticule Asia Macro Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2021, closing a stake of 66,000 shares — an estimated $1.04M sold.

Graticule Asia Macro Advisors first reported a position in BCRX in Q1 2021 and held it in 2 quarters. The position peaked at $1.04M in Q2 2021. 197 funds tracked by Wall St. Rank hold BCRX as of Q3 2021.

  • Graticule Asia Macro Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 66,000 BioCryst Pharmaceuticals shares in Q3 2021, an estimated $1.04M.
  • Graticule Asia Macro Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Graticule Asia Macro Advisors's BioCryst Pharmaceuticals position peaked at $1.04M in Q2 2021.
  • 197 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2021.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.